Drug Information Association Logo
Corporate Tagline

Asia Regulatory Conference 2013

Jan 28 2013 7:00AM - Jan 30 2013 5:00PM | Raffles City Convention Centre 252 North Bridge Road Singapore 179103 Singapore

« Back to Listing

Overview 

Limited seating available. Onsite registration on Monday.


Join health authority representatives and industry professionals from Asian and ICH member countries as they continue to discuss regulatory aspects of ICH, APEC and ASEAN convergence initiatives, good regulatory practices, quality and GMP, global drug development, and pharmacovigilance.

As of November 7, 2012 payment for the meeting will be in Singapore Dollars.  If you have downloaded a registration form before November 7th please discard and download a new copy from our website.

Who Should Attend 

Representatives of Health Authorities, Regulatory Affairs professionals, and other professionals involved in or interested in the aspects surrounding registration of medicinal products and regulatory convergence initiatives in Asia.

In particular professionals involved in:

  • Ministries of Health and Medicines Regulatory Authorities
  • Regulatory Affairs
  • Clinical Research and Development Safety and Pharmacovigilance
  • Clinical Trial and Project Management
  • CMC/Quality (Quality, Manufacturing and Controls)

Learning Objectives 

This three-day conference offers a unique opportunity for key stakeholders from health authorities, local and multinational pharmaceutical companies, and clinical research to meet and exchange views, discuss topics of interest and identify focus areas for ongoing efforts to increase patient access to new and improved medicines. This conference will provide a forum to:

  • Facilitate discussion on common issues in the regulatory and technical areas in Asia
  • Encourage greater convergence of regulatory requirements in Asia
  • Strengthen cooperation between Asian regulatory authorities and pharmaceutical industry

Conference speakers will include top-level regulatory authorities from several Asian countries as well as leading experts in the ICH process. In addition, speakers will include representatives of various regulatory agencies from other regions and the multinational and local pharmaceutical industry.

Hotel & Travel 

Conference Facility:
Raffles City Convention Centre
252 North Bridge Road
Singapore
179103

DIA does not have a dedicated hotel room block for this program. The Fairmont Singapore and the Swissôtel – The Stamford are the closest hotels to the Convention Center. Contact information for both of these facilities is as follows:

Fairmont Singapore
80 Bras Basah Road
Singapore
189560
Tel + 65 6339 7777
Fax + 65 6337 1554
Toll Free: 1 888 340 5959
Email: singapore@fairmont.com
Website: http://www.fairmont.com/singapore/
For Reservations call 1-800-257-7544
International Numbers

Swissôtel The Stamford
2 Stamford Road
Singapore
178882
Tel: +65 6338 8585
Fax: +65 6338 2862
Email:  singapore-stamford@swissotel.com
Website: http://www.swissotel.com/hotels/singapore-stamford/
For Reservations call: 1-800-637-9477
International Numbers

Singapore has many hotel options available. Should you wish to review other area hotels the Hotelopia website comes recommended. They will be happy to assist you with a reservation.

The Official Singapore Tourism Website is another excellent resource and will be happy to provide assistance.

Contact Information 

Registration Questions
Tim Hershey, Customer Service Team Lead
Phone +1.215.442.6157
Fax +1.215.442.6199
Tim.Hershey@diahome.org

Agenda and Event Details
Ellen Diegel, Event Planner
Phone +1.215.293.5810
Fax +1.215.442.6199
Ellen.Diegel@diahome.org

Tabletop Exhibit Information
Jeff Korn, Exhibits Associate
Phone +1.215.442.6184
Fax +1.215.442.6199
Jeff.Korn@diahome.org

Program Committee 

Previous Next

Agenda  

Day 1 Monday, January 28, 2013

  • 9:00AM - 9:30AM

    Opening Ceremony

    Speaker(s):

    • Welcome from the Drug Information Association (DIA)
      Ling Su, PhD
      Strategic Advisor, Life Sciences
      Sidley Austin LLP, China
    • Welcome from the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and Japan Pharmaceutical Manufacturers Association (JPMA)
      Toshiaki Miyoshi
      Managing Director
      Japan Pharmaceutical Manufacturers Association, Japan
    • Program Chairpersons Opening Remarks
      Arun Mishra
      Senior Director, Global Regulatory Affairs - EMAP Region
      GlaxoSmithKline, United Kingdom
    • Welcome Remarks by Guest of Honour
      Amy Khor, PhD
      Minister of State
      Ministry of Health and the Ministry of Manpower, Singapore
  • 9:30AM - 10:30AM

    Regulators and Industry Working Together to Have Safer and Better Access to Medicine

    Speaker(s):

    • Regulators and Industry Working Together to Have Safer and Better Access to Medicine
      John C W Lim, MD,MS,MSc
      Chief Executive Officer
      Health Sciences Authority, Singapore
    • Cooperation Between Drug Regulators & Industry
      Barbara J Sabourin, FACP
      Director General
      Health Canada (HPFB), Canada
  • 11:00AM - 12:00PM

    Path to the Future: Status and Future of Research and Development


    Session Chair(s):

    • No-image Yves Juillet, MD
      Senior Vice-President
      Industrie Sante, France

    Science is constantly moving forward. Implementing these new concepts or even creating them in drug Research and Development is key. It implies for Regulatory Authorities and Industry researchers a permanent adaptation to these new paradigms thanks to the development of Regulatory Science.

    Speaker(s):

    • Advancing the Science of Medicines Regulation: The Role of the 21st Century Medicines Regulator
      Murray M. Lumpkin, MD,MSc
      Commissioner's Senior Advisor and Representative for Global Issues, OC
      FDA , United States
    • Speaker
      James Garner, MA,MBA
      Vice President & General Manager
      Takeda Global Research & Development Center (Asia), Singapore
  • 1:30PM - 3:00PM

    Asia’s Role in Drug Development: A Global and Regional Perspective


    Session Chair(s):

    • Romi Singh, PhD
      Executive Director, Global Regulatory Affairs and Safety
      Amgen Inc., United States
    • Tomas Salmonson, PhD
      CHMP Chairman
      MPA, Sweden

    Historically, drug registrations in Asia followed, and to a large extent depended on, the Western drug development. However, over the recent years, there has been an increasing trend of Asia becoming a hub of global drug innovation and development. This session will discuss how Asia contributes to the global drug development and provide examples of how data generated primarily in Asia is used for registration in the West (US, EU).

    Speaker(s):

    • Contribution of Asia in Execution of Global Clinical Trials
      Yoshimasa Shimoto, PhD
      Vice President, Asia Development (Region Head)
      Daiichi Sankyo Co., Ltd., Japan
    • Asia's Role in Drug Development - an European Perspective
      Tomas Salmonson, PhD
      CHMP Chairman
      MPA, Sweden
    • Concept of Adaptive Licensing and Its Feasibility for a New Pathway of Drug Development from the Regional and Global Regulators' Perspective
      Raymond S.B. Chua, MD,MBA,MPH,FRCP
      Group Director, Health Products Regulation Group
      Health Sciences Authority, Singapore
  • 3:45PM - 5:15PM

    Asia's Role in Drug Development: A Global and Regional Perspective - continued

    Speaker(s):

    • Asia’s Role in Drug Development: A Global and Regional Perspective - continued
      Joseph C. Scheeren, PharmD
      Senior Vice President, Head Global Regulatory Affairs
      Bayer Healthcare Pharmaceuticals, United States
    • Innovative R&D Approaches: Opportunities in Asia
      Jogarao V. Gobburu, PhD,MBA
      Professor, School of Pharmacy and School of Medicine
      University of Maryland, United States
    • Asian Collaboration of Safety Biomarker Qualification Activity in Near Future
      Etsuko Usui
      Manager
      Novartis Pharma K.K., Japan

Day 2 Tuesday, January 29, 2013

  • 9:00AM - 10:45AM

    Global Review Practices: Industry & Regulatory Working Together


    Session Chair(s):

    • No-image Cordula Landgraf, RPh
      Head of Networking
      Swissmedic, Switzerland
    • Steven K Galson, MD,MPH
      VP Global Regulatory Affairs
      Amgen Inc., United States

    “Coming Together is a Beginning, Keeping Together is Progress, Working Together is Success” (Henry Ford) In this sense, the session will look at how Industry and Regulatory already work together and what could be done by both sides in terms of effective and efficient review processes to further strengthen and improve this co-operation. Is the model of work sharing between Regulatory Agencies the way to enable effective resource utilization to finally streamline approval? And how could the review process evolve to balance early access to new drugs with the need for comprehensive data?

    Speaker(s):

    • Elements of an Effective and Efficient Review Process from an Agency Point of View
      Dato' Eisah A. Rahman
      Senior Director of Pharmaceutical Services
      Ministry of Health Malaysia, Malaysia
    • How Does Industry See the Review Process Evolving to Address the Needs of Tomorrow?
      Paul D. Huckle, PhD,MPharm,RPh
      Senior Vice President, Global Regulatory Affairs
      GlaxoSmithKline, United States
    • Is there an Internationally Acceptable Framework for Benefit-Risk Assessment of Medicines that will enable a Regulatory and Industry collaboration for improved decision making?
      Stuart Walker, PhD
      Founder
      Centre For Innovation In Regulatory Science (CIRS), United Kingdom
    • Results of APEC Good Review Practices (GRP) Project
      Chao-Yi Wang, MSc
      Deputy Director, Division of Drugs and New Biotechnology Products
      TFDA, Taiwan
  • 11:15AM - 12:30PM

    Global CMC Reviews: Challenges and Opportunities


    Session Chair(s):

    • Lucky Surjadi Slamet, MSc
      Deputy,Therapeutic Prod, Narcotics, Psychotropic and Addictive Substance Control
      NADFC, The Republic of Indonesia, Indonesia
    • Chi-Wan Chen, PhD
      Executive Director, Global CMC, Global Research & Development
      Pfizer Inc, United States

    This session will discuss CMC challenges that are faced by the industry in obtaining a right first time approaches to securing successful filing and regulatory approval of pharmaceuticals, biological and vaccines in Asia. The session will cover not only the challenges encountered by industry but also the available opportunities for ensuring a smooth filing and approval from a regulator perspective.

    Speaker(s):

    • CMC Review: Challenges and Opportunities - Singapore HSA Perspective
      Dinesh Khokal, PhD,MSc
      Regulatory Consultant, Generics & Biosimilars Branch
      Health Sciences Authority, Singapore
    • Changes in CMC Submission and Review
      Zhen Chen, PhD
      Deputy Office Director, Office of New Drug Pharmaceutical Science
      Center for Drug Evaluation of CFDA , China
    • Challenges to Multi-National Companies in a Global Regulatory Environment – with Case Studies
      Chi-Wan Chen, PhD
      Executive Director, Global CMC, Global Research & Development
      Pfizer Inc, United States
  • 11:15AM - 12:30PM

    Clinical Reviews


    Session Chair(s):

    • Mark J. Goldberger
      Vice President, Regulatory Intelligence and Policy
      Abbott Laboratories Inc., United States

    Participants will hear from regulators and from industry about the critical elements of a product review. How do regulators "get the most bang for their buck and what are they most likely to be looking for. There will also be a discussion of the steps that a sponsor can take to facilitate the review process.

    Speaker(s):

    • Role of Clinical Review in SFDA/CDE: Yesterday, Today and Tomorrow
      Yi Feng
      Office of Evaluation Management and Communication
      Center for Drug Evaluation of CFDA , China
    • How to Win the Lottery on the Review Process
      Krishna Prasad, MD,FRCP
      Clinical Assessor/Consultant Cardiologist
      Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom
    • Sound Clinical Reviews: Mind over Matter - Any Role for the Heart?
      Aamir Shaikh, MD
      Founder
      Assansa, India
    • Panelist
      Ning Li, MD,PhD
      Vice President, GRA Head, Medical Policy, Asia
      Sanofi, China
  • 2:00PM - 3:30PM

    Biosimilars


    Session Chair(s):

    • Cecil J. Nick, MS
      FTOPRA, Vice President (Technical)
      PAREXEL Consulting, United Kingdom

    Biosimilarity is a concept first introduced into European legislation almost a decade ago to allow regulatory approval of similar biological medicines following submission of limited yet targeted data showing similarity to the reference biological product based on the totality of physico-chemical, biological, non—clinical and clinical testing. This concept has now spread across the globe with guidelines and regulations issued by all major regulatory agencies including WHO and those in US, Japan, Canada and Korea. This session will explore various view points on the critical considerations applicable to making affordable yet safe and effective similar biological medicines available globally.

    Speaker(s):

    • Biosimilarity and the Challenges in Desigining a Global Regulatory Program
      Cecil J. Nick, MS
      FTOPRA, Vice President (Technical)
      PAREXEL Consulting, United Kingdom
    • The Regulatory Pathway of Biosimilars - From Regulatory Guidance to the Assessment of Data
      Pekka T Kurki, MD,PhD
      Research Professor
      Finnish Medicines Agency, Finland
    • A Global Regulatory Biosimilar Program - Rising to the Challenge
      Heui Yun Joo
      Manager, Purification Process Team
      Celltrion Inc., Korea, Republic of
  • 2:00PM - 3:30PM

    Supply Chain Integrity: From Clinical Trials to Market


    Session Chair(s):

    • Brian Johnson
      Senior Director, Supply Chain Security
      Pfizer Inc, United States

    Supply chain security threats to our industry are on the rise globally. Collaboration is essential between all stakeholders in the supply chain to fight these crimes. This session will explore the threats our industry faces and any trends we are seeing. We will explore the benefits of a holistic approach to the problem from different stakeholder perspectives and explore the following questions. How can manufacturers organize around these threats? How can trade organizations help facilitate industry wide collaboration? How can regulatory convergence help? What specific initiatives are mobilizing in the Asia / Pacific region? We hope to shed some light on the problem and discuss mechanisms to prevent, detect, and respond to supply chain security threats.

    Speaker(s):

    • Supply Chain Security from a Pharmaceutical Company Perspective
      Brian Johnson
      Senior Director, Supply Chain Security
      Pfizer Inc, United States
    • APEC RHSC Regulatory Harmonization Steering Committee
      C. Michelle Limoli, PharmD
      Director, Harmonization and Multilateral Relations Office, OC
      FDA, United States
    • APEC Supply Chain Security Strategy
      Mark Paxton, JD,PhD
      Regulatory Counsel, OC, CDER
      FDA, United States
    • Supply Chain Security - the Role of an Industry Consortium
      Tim Valko
      Executive Director, Risk Management
      Amgen, United States
  • 4:00PM - 5:30PM

    ASEAN Regulator Working Group Panel Discussion


    Session Chair(s):

    • Vincent I. Ahonkhai, MD
      Senior Regulatory Officer, Global Health Delivery
      Bill & Melinda Gates Foundation, United States
    • Dato' Eisah A. Rahman
      Senior Director of Pharmaceutical Services
      Ministry of Health Malaysia, Malaysia

    DIfferences in the regulatory requirements of individual ASEAN Member States has a huge impact on economic growth, social progress, and cultural development. This panel will discuss how the ASEAN Regulator Working Group is working to eliminate technical battiers to trade posed by regulations without compromising product quality, efficacy and safety. Panel members will highlight achievements made toward regulatory convergence through shared practices, work-sharing and transparency.

    Speaker(s):

    • Panelist
      Siti Aida Abdullah
      Deputy Director
      Ministry of Health Malaysia, Malaysia
    • Panelist
      Wilai Bundittanugula
      Former Director
      Ministry of Public Health, Thailand
    • Panelist
      Marie Tham, RPh
      Advisor (International Collaboration), Health Products Regulation Group
      Health Sciences Authority, Singapore, Singapore
    • Panelist
      Rosni Jair
      Senior Scientific Officer, Drug Quality Section
      Ministry of Health, Brunei Darussalam
    • Panelist
      Soulyvanh Keokinnaly
      Technical Officer, Food and Drug Department
      Ministry of Health Lao PDR, Lao People's Democratic Republic
    • Panelist
      Kenneth Y Hartigan-Go, MD
      Professor, Dept. of Pharmacology, College of Medicine
      University of Philippines, Philippines

Day 3 Wednesday, January 30, 2013

  • 9:00AM - 10:30AM

    Emerging Trends


    Session Chair(s):

    • Alistair Davidson
      Senior Director, Global Regulatory Development, Asia Pacific
      PPD, United Kingdom
    • Toshiyoshi Tominaga, PhD
      Professor and Director, Center for Drug and Food Clinical Evaluation
      Osaka City University Hospital (OCUH), Japan

    This session will oversee some upcoming topics which are likely to need serious regulatory consideration in Asia in the near future. These may be already developed to some form in other parts of the world, but are still evolving and this gives an opportunity for the regulatory authorities in Asia as well as Industry partners to start to consider how these issues can be incorporated within the ongoing regulatory timetable. Heath Technology Assessments is a key area for the near-medium term as governments and regulatory authorities strive to deliver access of the best possible healthcare products, while keeping the costs under control. Other presentations will look at emerging technical challenges which will pose questions for regulators and Industry in the region over the next few years.

    Speaker(s):

    • Evolving the Fourth Pillar: Health Technology Assessments (HTAs) in Asia
      David Grainger
      Global Public Policy Director
      Eli Lilly & Company, Australia
    • Globalization and Individualization
      Toshiyoshi Tominaga, PhD
      Professor and Director, Center for Drug and Food Clinical Evaluation
      Osaka City University Hospital (OCUH), Japan
    • Bringing Transparency, Quality and Predictability in Indian Regulatory Environment – An Example of e-Governance in Gujarat State of India
      Hemant Koshia
      Commissioner
      Food and Drugs Control Administration, Gujarat, India
  • 11:00AM - 12:30PM

    Asia Regional Update on Convergence


    Session Chair(s):

    • Jerry Stewart, JD,MS,RPh
      Regulatory Policy Head, Emerging Markets
      Pfizer, United States
    • Chao-Yi Wang, MSc
      Deputy Director, Division of Drugs and New Biotechnology Products
      TFDA, Taiwan

    This session will present both industry’s and the regulatory authorities’ views on the status of regulatory convergence in Asia. Examples of Regulatory convergence and divergence will be discussed, including recommendations on how to progress more convergence in areas such as clinical development, submission standards, risk-benefit assessments and approval time lines. Highlights from APEC RHSC, PhRMA and other organizations will help to paint a picture of the current regulatory environment and emerging topics on harmonization for attendees to consider.

    Speaker(s):

    • Overview of Regulatory Convergence in Asia
      Gloria Hung
      Senior Manager - RA
      Pfizer CORPORATION HONG KONG LIMITD, Hong Kong
    • Recent Convergence Efforts
      Justina A. Molzon, JD,MPharm
      Associate Center Director for International Programs, CDER
      FDA, United States
    • Industry's Role in APEC RHSC
      Wen Chang, PhD
      Vice President, North Asia Strategy and China Regulatory Sciences
      Bristol-Myers Squibb Company, China
    • TFDA's View on Regulatory Harmonization and Its Efforts to Implement It
      Chao-Yi Wang, MSc
      Deputy Director, Division of Drugs and New Biotechnology Products
      TFDA, Taiwan
  • 12:30PM - 12:45PM

    The World Bank: Overview Regulatory Harmonization Activities in the ASEAN Region
  • 2:00PM - 3:30PM

    Counterfeit


    Session Chair(s):

    • Ruth Lee
      Director, Enforcement Branch
      Health Sciences Authority, Singapore
    • Raymond H. Velez
      Regional Manager, South Asia Pacific, Global Product Protection
      Eli Lilly (Singapore) Pte., Ltd., Singapore

    Counterfeit medical products pose a significant danger to public health in both developing and developed countries. The global nature of manufacturing and trade in medical products makes it crucial that all countries work together in a concerted effort to reduce the growing market for counterfeit medical products. In this session, three key speakers representing WHO, INTERPOL and Pharmaceutical Security Institute (PSI) will highlight their respective roles and responsibilities, as well as their efforts in combating this global problem of counterfeit medical products. Sensitivities surrounding this topic and the challenge of achieving effective collaborations among all stakeholders to achieve the common goal of protecting public health and safety will also be discussed.

    Speaker(s):

    • INTERPOL's Successful Model in Combating Cyber Pharmaceutical Crime
      Cecilia Fant
      Superintendent
      INTERPOL, France
    • PSI - A Unique Ally and Key to Effective Partnerships
      Thomas T. Kubic
      President & CEO
      Pharmaceutical Security Institute, United States
    • Counterfeit and Supply Chain
      Mohd Hatta Bin Ahmad
      Director of Pharmacy Enforcement Division
      Ministry of Health Malaysia, Malaysia
  • 2:00PM - 3:30PM

    Pharmacovigilance and Risk Management


    Session Chair(s):

    • Kenneth Y Hartigan-Go, MD
      Professor, Dept. of Pharmacology, College of Medicine
      University of Philippines, Philippines
    • Florence Houn, MD,MPH,FACP
      FDA Alumni Association; Celgene, United States

    It is well recognized that despite rigorous pre-market regulation process, post-market surveillance is essential to ensure that the benefit/risk balance of health products remains favourable throughout the product’s lifecycle. In the recent years, known or potential safety issues that require monitoring are identified prior to product registration and ways of communicating these issues to healthcare professionals and patients, as well as enhanced surveillance methods are developed. These risk mitigating strategies are presented in the form of a risk management plan, specific for each product. In this session, representatives from both regulatory agencies and the industry will share on elements of pharmacovigilance and the implementation of risk management plans.

    Speaker(s):

    • Pharmacovigilance in Singapore
      Cheng Leng Chan
      Deputy Group Director, Health Products Regulation Group
      Health Sciences Authority, Singapore
    • Pharmacovigilance Updates in Japan and Risk Management Plans
      Kosuke Haneda, PhD
      Pharmaceuticals and Medical Devices Agency (PMDA), Japan
    • New EU Legislation: Impact on Risk Management and Post Market Surveillance in Asia
      Siew Huey Liew
      Associate Manager, Drug Safety and Epidemiology
      Novartis (Singapore) Pte., Ltd., Singapore
    • Current Challenges to Cope with Risk Management of Medicines
      Hubert G. M. Leufkens, PharmD
      Chairman
      Dutch Medicines Evaluation Board, Netherlands
  • 3:30PM - 4:30PM

    Path to the Future: Regulatory Panel Discussion


    Session Chair(s):

    • No-image Yves Juillet, MD
      Senior Vice-President
      Industrie Sante, France

    The purpose of this Regulatory Panel discussion at the close of the Conference is to gain and share insights on the practical meaning and implications of regulatory convergence and cooperation among regulators for the acceleration of patient access to medicines and the protection and promotion of the quality of medical products. After 3 days of sessions and discussions around the main theme of the Conference, this final session will aim to envision a path to a future of greater benefit for regional global patients – recognizing both the opportunities and the remaining challenges, and possible ways to address them. Based on the discussions during the first 3 days of the Conference, the Co-Chairs will identify 2-3 themes relevant to the Path to the Future and will solicit comments, from each panelist.

    Speaker(s):

    • Panelists
      Cordula Landgraf, RPh
      Head of Networking
      Swissmedic, Switzerland
    • Panelists
      Murray M. Lumpkin, MD,MSc
      Commissioner's Senior Advisor and Representative for Global Issues, OC
      FDA , United States
    • Panelists
      Toshiyoshi Tominaga, PhD
      Professor and Director, Center for Drug and Food Clinical Evaluation
      Osaka City University Hospital (OCUH), Japan
    • Panelists
      John C W Lim, MD,MS,MSc
      Chief Executive Officer
      Health Sciences Authority, Singapore
    • Panelists
      Dato' Eisah A. Rahman
      Senior Director of Pharmaceutical Services
      Ministry of Health Malaysia, Malaysia
  • 4:30PM - 5:00PM

    Closing Remarks

    Speaker(s):

    • Arun Mishra
      Senior Director, Global Regulatory Affairs - EMAP Region
      GlaxoSmithKline, United Kingdom
    • John C W Lim, MD,MS,MSc
      Chief Executive Officer
      Health Sciences Authority, Singapore

Exhibits  

The Asia Regulatory Conference 2013 offers interested companies the opportunity to exhibit with a tabletop display.

Tabletop Fee: SGD $4,300

Fee Includes:

  • One tabletop personnel registration
  • One skirted table
  • One chair
  • Standard electricity

Tabletop Exhibit Dates
January 28-30, 2013

Useful Links

  • Agilent Technologies
  • KoNECT
  • MakroCare
  • Real Staffing Group

Registration Fees 

Other Fees

Charitable Nonprofit/Academia
$980.00
Government (Full Time)
$740.00
Industry
$2400.00
Group Discounts

Register three individuals from the same company and receive complimentary registration for a fourth! All four individuals must register and prepay at the same time – no exceptions.
To take advantage of this offer, click on “View PDF” below and make four copies of the registration form. Complete the main registration for each of the four registrants and include the names of all other group registrants in the Group Discount section. DIA will apply the value of the lowest applicable fee to this complimentary registration; it does NOT include fees for optional events or DIA membership. You may substitute group participants of the same membership status at any time; however, administrative fees may be incurred.

Group registration is not available online and does not apply to the already-discounted fees for government or charitable nonprofit/academia.


Register Online
« Back to Listing Back To Top